NCT03590379View on ClinicalTrials.gov

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL

Enrollment

366

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

October 16, 2018

Study Completion Date

March 6, 2019

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

CHF 5993 DPI

BDP/FF/GB DPI

DRUG

CHF5993 pMDI

BDP/FF/GB pMDI

DRUG

CHF 1535 pMDI

BDP/FF pMDI

DRUG

Placebo DPI

CHF 5993 DPI matched placebo

DRUG

Placebo pMDI

CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)

Trial Locations (1)

1680

Medical Center Convex EOOD, Sofia

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT03590379 - Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter